First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy

First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy

On-Demand Webcast

John N. Allan, MD
Weill Cornell Medicine
New York, New York

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Boston, Massachusetts

Silvia Deaglio, MD, PhD
University of Turin
Turin, Italy

Richard R. Furman, MD
Weill Cornell Medicine
New York, New York

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Thomas J. Kipps, MD, PhD
University of California
La Jolla, California

Jennifer A. Woyach, MD
Ohio State University
Columbus, Ohio

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.


Chronic lymphocytic leukemia (CLL) is the second most-common leukemia type in adults. The disease is considered to be incurable and is expected to be diagnosed in nearly 22,000 people in the United States in 2019; of those people, nearly 4,000 will die from the disease. Thus, CLL remains a burden to the healthcare system and to the patients and their families who are affected by this malignancy.
With the advent of targeted therapies for the treatment of CLL, the therapeutic landscape has shifted dramatically in recent years. Using new mechanisms of action, novel treatments, including Bruton’s tyrosine kinase (BTK) inhibitors, anti-CD20 monoclonal antibodies (mAbs),  a BCL-2 inhibitor, and P13K inhibitors, and combinations of these novel treatments, have introduced the prospect of deep remission for many patients. This has led to new molecular methods for assessing minimal residual disease (MRD), the value of which for determining prognosis and treatment efficacy is currently emerging.

This webcast aims to update clinicians on new data and recommendations for the use of targeted therapies in first-line and second-line treatment of CLL.


Upon successful completion of this educational activity, participants should be better able to:

  1. Discuss patient factors that will influence first- and second-line treatment strategies for patients with CLL
  2. Outline data supporting targeted therapy as front-line treatment for CLL
  3. Incorporate prognostic information into first- and second-line treatment decisions for patients with CLL

Release Date: December 31, 2019

Expiration Date: December 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by educational grants from: AstraZeneca, Genentech, Janssen Biotech, and Pharmacyclics.



 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


NACCME designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 4.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 4.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 4.5 contact hours.


This knowledge-based activity (JA0006201-9999-20-042-H01-P) is approved for 4.5 contact hours (0.45 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises John N. Allan, MD, Matthew S. Davids, MD, MMSc, Silvia Deaglio, MD, PhD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, Jennifer A. Woyach, MD; and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

John N. Allan, MD, reports that he is a consultant for AbbVie, AstraZeneca, Cellectar, Genentech, Pharmacyclics, and Suneis; has received grant or research support from Janssen; and has received other financial support from AstraZeneca and Janssen.

Matthew S. Davids, MD, MMS, reports that he is a consultant for AbbVie, Acerta Pharma, Adaptive Biotechnologies, Genentech, Janssen, MEI Pharma, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, and Verastem Oncology; and has received grant or research support from Acerta Pharma, Ascentage Pharma, Genentech, MEI Pharma, Surface Oncology, TG Therapeutics, and Verastem Oncology.

Silvia Deaglio, MD, PhD, reports that she has received grant or research support from Sunesis iTeos, VelosBio, and Verastem Inc.

Richard R. Furman, MD, reports that he is a consultant Abbvie, Acerta, AstraZeneca, Beigene, Genentech, Incyte, Janssen, Loxo Oncology, Oncotracker, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem; has received grant or research support from Acerta, AstraZeneca, and TG Therapeutics; and has received other financial support from Incyte.

Neil E. Kay, MD, reports that he is a consultant for Agios Pharm, Astra Zeneca, Celgene, Cytomx Therapeutics, Dava Oncology, Infinity Pharm, Juno Therapeutics, MorphoSys, Pharmacyclics, and Rigel; and has received grant or research support from Acerta Pharma BV, MEI Pharma, Pharmacyclics, and Tolero Pharmaceuticals.

Thomas J. Kipps, MD, PhD, reports that he is a consultant for Abbvie, Genentech, Pharmacyclics, Octernal, Inc., and VelosBio; has received grant or research support from Abbvie, Pharmacyclics, Genentech, Oncternal, Inc., VelosBio; is a speaker for Abbvie, Genentech, and Pharmacyclics; and has received other financial support from Oncternal, Inc.

Jennifer A. Woyach, MD, has received grant or research support from Abbvie, Acerta, Janssen, Loxo, Karyopharm, Morphosys, and Pharmacyclics; and received other financial support from Janssen and Pharmacyclics.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.